Advancements in the Diagnosis and Treatment of Inflammatory Bowel Diseases
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 26
Special Issue Editor
Special Issue Information
Dear Colleagues,
The global burden of inflammatory bowel diseases is on the rise. Although pathophysiological mechanisms have been elucidated and new therapeutic options have expanded in the last 10 years, morbidity in terms of late damages of the bowel as well as impaired quality of life is still high. This applies especially for the diagnosis and treatment of extraintestinal manifestations (EIMs), e.g., of the liver or joints as well as cardiac complications through years of systemic inflammatory activity.
Therefore, this Special Issue has the aim to explore the latest advancements in the diagnosis and treatment of chronic inflammatory bowel diseases (IBDs). Emphasizing innovative diagnostic techniques, this issue dives into imaging modalities, biomarker identification, scoring quality of life, diagnostic work-ups of EIMs, and the utilization of endoscopic advancements to enhance diagnostic accuracy. A critical focus is placed on evaluating therapeutic responses, with discussions on personalized medicine approaches, biologic treatments, and novel small molecules. This series will also examine the integration of artificial intelligence (AI) in predicting disease course, optimizing treatment plans, and improving patient outcomes. Additionally, the impact of IBD on patients' quality of life will be addressed, with insights into comprehensive management strategies that address both physical and psychological aspects of the disease.
A combination of original articles as well as review articles will provide an overview of current and emerging practices in the management of IBD. By highlighting these aspects, this issue aims to inform healthcare professionals about the potential benefits and challenges of these innovations, hopefully contributing to improved patient care and quality of life for those affected by chronic inflammatory bowel diseases.
Dr. Thomas Klag
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chronic inflammatory bowel diseases (IBD)
- Crohn's disease (CD)
- ulcerative colitis (UC)
- therapy monitoring
- extraintestinal manifestations (EIMs)
- quality of life
- artificial intelligence (AI)
- personalized medicine
- personalized medicine
- endoscopic advancements
